AtCor Medical

Our SphygmoCor systems are the global gold standard in diagnosis and patient
management, pharmacutical clinical trials and research.

ATCOR MEDICAL INVESTOR

NEW Recent Interview with Australian Investor
AtCor Medical Significantly Progresses Towards its Goal of a Long Term, Financially Stable Position with over US$6.5 million New Pharmaceutical & Biotech Contracts Signed in the Past 8 Months.

Please click here to view the article.

Analysts' Reports
Taylor Collison Sharebrokers and Investment Advisers have initiated coverage of AtCor Medical Holdings Limited.

Please click here to view their reports.

VIEW PRODUCT DEMONSTRATION

The SphygmoCor system provides a quick and non-invasive method of obtaining key cardiovascular data thereby enhancing the treatment and management of patients.

Click below to view a brief demonstration of the steps involved in taking a SphygmoCor measurement.

Click here for demonstration

NEWS

19 May 2009 : 70% Sales Growth in FY09 Expected

23 April 2009 : Third Quarter Report - Appendix 4C

20 April 2009 : US$0.6 Million New Pharmaceutical Trial Contract

16 April 2009 : SphygmoCor Shows Drug Lowers Blood Pressure in Pre-Eclampsia Patients

15 April 2009 : US$0.8 Million New Pharmaceutical Trial Contracts